Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
National Institutes of Health
Sign in and complete your Funding Passport to see whether you qualify — a transparent, rule-based verdict, not a black box.
Sign InAbout this opportunity
The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Required documents
The official source lists no specific documents here — confirm requirements before applying.
Source & verification trail
- Official source
- U.S. Federal Government (Grants.gov) ↗
- First retrieved
- November 20, 2026
- Last verified
- November 20, 2026
- Content fingerprint
c5331377760e3a46…